Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies

References

• Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc. 2011;86:156–167.
   PubMed Web of Science ®Google Scholar
• Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:321–331.
   PubMedGoogle Scholar
• Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017;7:383–384.
   Google Scholar
• Borsch GM, Graham DY. Helicobacter pylori. In: Collen MJ, Benjamin SB, editors. Pharmacology of peptic ulcer disease. In: handbook of experimental pharmacology Vol 99. Berlin: Springer-Verlag; 1991. p. 107–148.
   Google Scholar
• Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology. 1998;115:1272–1277.
   PubMed Web of Science ®Google Scholar
• Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870–878.
   PubMed Web of Science ®Google Scholar
• Graham DY. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut. 2017;66:2043–2046.
   PubMed Web of Science ®Google Scholar
• Shiotani A, Lu H, Dore MP, et al. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017;84:310–318.
   PubMed Web of Science ®Google Scholar
• Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369:482–490.
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42.
   PubMed Web of Science ®Google Scholar
• Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742–750.
   PubMed Web of Science ®Google Scholar
• Reardon S. Antibiotic resistance sweeping developing world. Nature. 2014;509:141–142.
   PubMed Web of Science ®Google Scholar
• Pilotto A, Franceschi M, Rassu M, et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis. 2000;32:667–672.
   PubMedGoogle Scholar
• Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter. 1999;4:106–112.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–781.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection–the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646–664.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Graham DY, Lu H. Should triple therapy for Helicobacter pylori infection be abandoned as no longer effective? US Gastroenterology. 2008;4:65–67.
   Google Scholar
• Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter. 2011;16:343–345.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am. 2015;44:537–563.
   PubMed Web of Science ®Google Scholar
• Essa AS, Kramer JR, Graham DY, et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109–118.
   PubMed Web of Science ®Google Scholar
• Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23–34.
   PubMedGoogle Scholar
• Shapiro S. Meta-analysis/Shmeta-analysis. Am J Epidemiol. 1994;140:771–778.
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14:577–585.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177–186.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Shiotani A. Failure of optimized dual proton pump inhibitor amoxicillin therapy: what now? Saudi J Gastroenterol. 2017;23:265–267.
   PubMed Web of Science ®Google Scholar
• Graham DY. Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: effect of resistance, duration, and CYP2C19 genotype. Helicobacter. 2015;21:85–90.
   PubMed Web of Science ®Google Scholar
• Dyar OJ, Huttner B, Schouten J, et al. What is antimicrobial stewardship? . Clin Microbiol Infect. 2017;23:793–798.
   PubMed Web of Science ®Google Scholar
• Hulscher MEJL, Prins JM. Antibiotic stewardship: does it work in hospital practice? A review of the evidence base. Clin Microbiol Infect. 2017;23:799–805.
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–239.
   PubMed Web of Science ®Google Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51–69.
   PubMed Web of Science ®Google Scholar
• Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis. 2004;10:514–517.
   PubMed Web of Science ®Google Scholar
• Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514–533.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Dore MP. Empiric 4-drug non-bismuth Helicobacter pylori therapies promote misuse (overuse) of antibiotics. Helicobacter. 2016;21:139.
   Web of Science ®Google Scholar
• de Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol. 1996;22:313–316.
   PubMed Web of Science ®Google Scholar
• de Boer WA, Driessen WM, Potters VP, et al. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol. 1994;89:1993–1997.
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhang W, Fu Q, et al. Rescue therapy for Helicobacter pylori eradication: A randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol. 2016;111:1736–1742.
   PubMed Web of Science ®Google Scholar
• Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802–807.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64:1715–1720.
   PubMed Web of Science ®Google Scholar
• Cao Z, Chen Q, Zhang W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015;50:1185–1190.
   PubMed Web of Science ®Google Scholar
• Liao J, Zheng Q, Liang X, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18:373–377.
   PubMed Web of Science ®Google Scholar
• Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15:233–238.
   PubMed Web of Science ®Google Scholar
• Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol. 2009;15:860–864.
   PubMed Web of Science ®Google Scholar
• Choe JW, Jung SW, Kim SY, et al. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter. 2018;23:e12466.
   PubMed Web of Science ®Google Scholar
• Salazar CO, Cardenas VM, Reddy RK, et al. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: A pilot study in US Hispanics. Helicobacter. 2012;17:382–389.
   PubMed Web of Science ®Google Scholar
• Dore MP, Graham DY, Mele R, et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am .J Gastroenterol. 2002;97:857–860.
   PubMed Web of Science ®Google Scholar
• Dore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter. 2003;8:307–309.
   PubMed Web of Science ®Google Scholar
• Habing G, Djordjevic C, Schuenemann GM, et al. Understanding antimicrobial stewardship: disease severity treatment thresholds and antimicrobial alternatives among organic and conventional calf producers. Prev Vet Med. 2016;130:77–85.
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis. 2012;55:1031–1046.
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP. Update on the use of vonoprazan: A competitive acid blocker. Gastroenterology. Forthcoming 2018.
   Web of Science ®Google Scholar
• Ciccaglione AF, Tavani R, Grossi L, et al. Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies. Helicobacter. 2016;21:375–381.
   PubMed Web of Science ®Google Scholar